Fluoxetine to Reduce Hospitalization From COVID-19 Infection (FloR COVID-19)
Status:
Withdrawn
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The current research is a pilot study to determine the feasibility of recruiting and
retaining 40 participants diagnosed with COVID-19. The purpose is to observe the early use of
fluoxetine (commonly known as Prozac) to reduce the severity of the COVID-19 illness.
Fluoxetine is a drug that has been approved by the U.S. Food and Drug Administration (FDA)
since 1987 for various mental health disorders.